Sleep Apnea Reduced in People Who Took Zepbound, Eli Lilly Reports
The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk ’s Wegovy.
Source: NYT Health - Category: Consumer Health News Authors: Gina Kolata Tags: Tirzepatide Apnea (Sleep Disorder) Drugs (Pharmaceuticals) Obesity Weight Clinical Trials Eli Lilly and Company Source Type: news
More News: Clinical Trials | Eating Disorders & Weight Management | Health | Obesity | Sleep Apnea | Sleep Disorders | Sleep Medicine